Clinical Trials Logo

Chronic Hepatitis C clinical trials

View clinical trials related to Chronic Hepatitis C.

Filter by:

NCT ID: NCT01274013 Withdrawn - Chronic Hepatitis C Clinical Trials

Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers

Start date: October 2009
Phase:
Study type: Observational

The objective of this study is to assess the prevalence of vitamin D deficiency in patients with chronic Hepatitis C compared to a matched control group of healthy individuals in the Sioux Falls area. It is the hypothesis of this study that vitamin D deficiency is more common in patients with chronic Hepatitis C compared to the healthy control group.

NCT ID: NCT01272310 Not yet recruiting - Chronic Hepatitis C Clinical Trials

Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.

Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The study is aimed to investigate the safety, tolerability and efficacy of a fixed dose combination therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (PEG-IFN alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C Genotype 1 Infected adult subjects who failed to respond following a course of PEG-IFN and RBV Therapy.

NCT ID: NCT01263860 Completed - Chronic Hepatitis C Clinical Trials

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients

Start date: December 2010
Phase: Phase 3
Study type: Interventional

Patients with HCV genotype 6 infection who have a rapid virological response to treatment are randomised to either 24 or 48 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.

NCT ID: NCT01226446 Completed - Chronic Hepatitis C Clinical Trials

Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders

ANRS VITAVIC
Start date: November 2010
Phase: Phase 2
Study type: Interventional

Vitamin D deficiency is commonly found in patients with chronic hepatitis C. The investigators hypothesize that the correction of hypovitaminosis D before the initiation of anti-HCV combination therapy and the maintenance of an optimal vitamin D status during antiviral therapy could improve the antiviral efficacy

NCT ID: NCT01210404 Completed - Chronic Hepatitis C Clinical Trials

Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance

Start date: February 2011
Phase: Phase 1
Study type: Interventional

Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C infection. Given the likelihood of co administration of filibuvir and methadone, this study will evaluate the effect of filibuvir on the pharmacokinetics of R/S Methadone.

NCT ID: NCT01178996 Completed - Chronic Hepatitis C Clinical Trials

Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

Start date: December 2004
Phase: Phase 3
Study type: Interventional

The purpose of the study was to determine safety and efficacy of 48 weeks treatment with Thymosin alpha 1 (Talpha1) in combination with pegylated interferon (PEGIFN) alpha2a and ribavirin (RBV) in adult patients with chronic hepatitis C (CHC) already treated with, and not responding to previous courses of PEGIFN alpha plus RBV combination therapy, in comparison with a concurrent group treated with PEG IFN alpha2a in combination with RBV and placebo.

NCT ID: NCT01178749 Recruiting - Chronic Hepatitis C Clinical Trials

Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments

Start date: September 2007
Phase: N/A
Study type: Observational

The aims of this three-year study are to explore symptom experience and its related factors for the patients with chronic hepatitis C Infection receiving interferon-α with ribavirin for 24 weeks and further to predict the relative risk of failure or occurence of severe side effects which interrupt the treatment.

NCT ID: NCT01159613 Completed - Clinical trials for Chronic Hepatitis C Viral Infection

Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?

Start date: April 2008
Phase: N/A
Study type: Observational

The working hypothesis is that the low HDL serum level predict favorable response to anti viral treatment in chronic HCV (genotype 1) viral infection. This might be used to improve the rate of sustained virologic response.

NCT ID: NCT01157104 Completed - Chronic Hepatitis C Clinical Trials

A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between IDX320 and IDX184 and to assess the safety and tolerability when the two drugs are administered in combination in healthy participants.

NCT ID: NCT01151397 Not yet recruiting - Chronic Hepatitis C Clinical Trials

Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?

Start date: August 2011
Phase: N/A
Study type: Interventional

Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 80% of naïve patients with genotype 2,3. Studies rarely address the issues of improving host factors. The current study examines 1. Does 3 months therapy with Vitamin D+ Peg + Ribavirin could improve viral response and shorten treatment duration (from 24 weeks to 12 weeks) 2. whether Vitamin D levels predicts negative treatment outcome.